Biological
UCAR T-cell group
UCAR T-cell group is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph early_phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
3(100.0%)
Highest Phase Reached
Early Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Not yet recruiting2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 13 (100.0%)
Trials by Status
not_yet_recruiting267%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingearly_phase_1
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
NCT06920433
not_yet_recruitingearly_phase_1
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
NCT06933563
not_yet_recruitingearly_phase_1
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Autoimmune Hemolytic Anemia
NCT06920446
Clinical Trials (3)
Showing 3 of 3 trials
NCT06920433Early Phase 1
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
NCT06933563Early Phase 1
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
NCT06920446Early Phase 1
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Autoimmune Hemolytic Anemia
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3